Focused On-demand Library for Annexin A11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P50995

UPID:

ANX11_HUMAN

Alternative names:

56 kDa autoantigen; Annexin XI; Annexin-11; Calcyclin-associated annexin 50

Alternative UPACC:

P50995; B4DVE7

Background:

Annexin A11, also known as a 56 kDa autoantigen, Annexin XI, and Calcyclin-associated annexin 50, plays a crucial role in cellular processes. It binds specifically to calcyclin in a calcium-dependent manner, a key interaction for midbody formation and successful completion of cytokinesis. This protein's involvement in cell division underscores its fundamental importance in biology.

Therapeutic significance:

Annexin A11's association with diseases such as Amyotrophic lateral sclerosis 23 and Inclusion body myopathy with brain white matter abnormalities highlights its potential as a therapeutic target. Understanding the role of Annexin A11 could open doors to potential therapeutic strategies, especially considering its involvement in neurodegenerative disorders and muscle weakness conditions.